Description: Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression. Target: Autophagy, EGFR, Ferroptosis. Smiles:...

Lapatinib is a dual inhibitor of the EGF receptor (EGFR) and ErbB2 (IC50s = 19 and 3 nM, respectively). It inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 µM, respectively). Lapatinib also inhibits the growth of ErbB2-amplified...

Inhibitor of EGFR/HER2 (ErbB2).

ATP-competitive EGFR & ErbB-2 dual tyrosine kinase inhibitor. Lapatinib is an ATP-competitive epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor, with IC(50) values of 10.8 and 9.2nm respectively. It is an orally active drug for treatment of breast cancer and other solid...

Soluble in DMSO or ethanol. Lapatinib is an ATP-competitive epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor, with IC(50) values of 10.8 and 9.2nM respectively. It is an orally active drug for treatment of breast cancer and other solid tumors. Target: EGFR , Kinase...